Event in Progress:
Discover the latest content that has just been published on Research Tree
Amgen had an eventful 2022. The company carried out some major acquisitions in the year including the $3.7 billion purchase of ChemoCentryx followed by the even bigger, $27.8 billion acquisition of Horizon Therapeutics. The company’s financial performance in the last quarter was also strong as its growing general medicine and hematology-oncology brands experienced significant volume increases. With the introduction of TEZSPIRE and the acquisition of TAVNEOS, two first-in-class medications that t
Companies: AMGEN (AMGN:NYSE)Amgen Inc. (AMGN:NAS)
Baptista Research
Despite the challenges in the macroeconomic environment and the pharmaceutical business, Amgen’s stock has been on a strong upward trajectory over the past weeks. The company delivered a solid result where it surpassed Wall Street expectations on all counts. Volumes increased by 8% and 16% outside of the United States in Q3, showing the benefit of that strategy. During the quarter, they closed the acquisition of ChemoCentryx and included Tavneos, a drug used to treat anti-neutrophil cytoplasmic
Amgen delivered strong volume-driven growth in the last quarter which resulted in the company managing an all-around beat. Many of the innovative products of the company performed quite well, namely Evenity, Prolia, Otezia, and Repatha, all of which delivered sales growth of double-digits. Two of the company's new products, Tezspire and Lumakras, are both off to a great start. Lumakras is being prescribed to patients with non-small cell cancer worldwide. Meanwhile, Tezspire has made a large impa
Companies: Amgen Inc. (AMGN:NAS)Amgen Inc. (0R0T:LON)
Amgen started off with 2022 on a positive note generating 6% revenue growth and 15% earnings per share growth. The company’s drugs Repatha, Prolia, and Evenity were responsible for a 9% increase in product sales. However, the company’s net selling price declined, and foreign exchange headwinds partially offset volume growth. Amgen also saw strong volume growth outside of the United States of 15% in Q1 and nearly 30% volume growth in the Asia Pacific region, which is an important component of its
Biogen has been going through a rough patch off-late. One of its core drugs, Tecifidera's revenue continued to erode in the U.S. due to generic entry. In light of several recent challenges, the company announced that it would implement cost-cutting measures expected to save approximately $500 million annually. On the other hand, they recently announced a deal to sell their Samsung Bioepis joint venture stake to Samsung Biologics, with Biogen continuing to be the commercialization partner for the
Amgen has continued to benefit from strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings. The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests. Teneobio's acquisition, when combined with Nuevolution's DNA encoded library technology, gives Amgen the ability to develop both large and small molecule multi-specifics. Besides, The compan
Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings. The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests. Teneobio's acquisition, when combined with Nuevolution's DNA encoded library technology, gives the company the ability to dev
Amgen experienced another solid quarter of growth, with total revenues increasing by 4%, driven by volume growth of 8%. The robust performance was a result of strong global demand for many of its innovative offerings such as Repatha and Prolia, as well as its high-quality biosimilars. Besides, the management is excited about tezepelumab, a first-in-class treatment for severe asthma that they are looking to launch in the U.S. in 2022. Given the loads of patients for whom current asthma treatments
Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for its offerings. The company’s total revenue grew by 5% in Q2 compared to the previous year and 11% compared to the previous quarter. Its performance in non-U.S. markets was noteworthy and saw a 22% volume growth. Biosimilars were also a major contributor to the top-line. Sadly, a trimmed guidance for the rest of 2021 resulted in the stock price witnessing
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: IMM IBAB 0O8G BCART 0QLR RHO5 MRCK 0QXH VSC 0QGJ SANO 0OCQ IPH GSK AZN 0Y6X QGEN 0HL9 0GRZ EJXB 0Q15 ABBV 0HAV 0RIH 0R0T BMYS EXK 0J8Z 0R29 0R34 0K3W NSTGQ 0KCC 0Q1N SGEN 0R0H 12V VNRX XE9
goetzpartners securities Limited
Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare
Companies: PLI SAR BLU SKP INS SCLP HVO OXB OPTI ONC HCM 0R0T 0HNC 0L35 1S9
Hybridan
Research Tree provides access to ongoing research coverage, media content and regulatory news on Amgen Inc.. We currently have 22 research reports from 5 professional analysts.
Companies: BILN IGP RBN SBTX
Cavendish
Verici’s $8.2m gross raise means the company can now focus on scaling Tutivia and invest further into the development of existing and new products. With a uniquely well balanced Tutivia test, a growing sales team and LCD coverage expected later this year, we forecast Tutivia revenues of $2.6m/$4.5m in FY24E/FY25E. The Thermo Fisher deal was a huge validation of Clarava and Verici’s technology and in addition to licensing/milestone payments, we forecast double digit royalties on net Clarava sales
Companies: Verici Dx Plc
Singer Capital Markets
26th March 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: BIRD MBH CHRT INSE KMK FNTL HDD JNEO CCS
Companies: Aptamer Group Plc
Turner Pope Investments
SkinBioTherapeutics has reported on the 6-months to December 2023, noting steady revenue growth from lead product AxisBiotix-Ps, progress on the development of SkinBiotix with partner Croda (Sederma) and post-period end, the acquisition of Dermatonics. The company has updated on several positive developments through the start of 2024, including AxisBiotix Acne positive interim results, initiation of research on the MediBiotix Pillar and progress with the oral and inflammation programmes. The com
Companies: SkinBioTherapeutics Plc
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Hardman & Co
Companies: CLBS GHH NANO TRX SAVE TMT GELN
On 18th December 2023 Incanthera announced a deal with Marionnaud in Switzerland to distribute ‘Skin+CELL’, its advanced dermatological solution for the delivery of vitamin B3 for skin protection and cosmetic rejuvenation. This gives Incanthera access to a high-end cosmetics distribution presence in Europe, and in addition, ownership of Marionnaud by AS Watson, the largest cosmetics distributor in Asia, offers significant new market opportunities further afield.
Companies: Incanthera Plc
Stanford Capital Partners
FY EBITDA and EBIT came in materially above consensus FY EBITDA came in at EUR98.8m, down 4% yoy and 12% above consensus. The EBITDA margin was 12.6%. Restated for one-off costs, it was 13.1%, more than 2 percentage points above the guidance. It was fully explained by price increases, notably on X-ray, mix and control of fixed costs. FY EBITA came in at EUR38m, 46% above consensus. 2024 guidance looks conservative Guerbet is aiming for organic growth above 8% (8.8%e). With markets growing at
Companies: Guerbet (GBT:EPA)Guerbet SA (GBT:PAR)
BNP Paribas Exane - Sponsored Research
IRLAB Therapeutics has confirmed the FDA’s alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following receipt of the minutes from its end-of-Phase II (EoP2) meeting held last month. Notably, the FDA has agreed on the primary endpoint being the Unified Dyskinesia Rating Scale (UDysRS), on which mesdopetam demonstrated a statistically significant improvement (p=0.026) in the Phase IIb study (secondary endpoint of that study). IRLAB will now
Companies: Irlab Therapeutics Ab
Edison
Tissue Regenix has reported on strong performance through 2023, noting record revenues driven by product adoption and expanded distribution, positive adjusted EBITDA for the first time and an increased cash position versus H1/23. FY23 revenues grew 20% to $29.5m supported by 25% growth from BioRinse products and 17% growth from dCELL products. Significantly, Tissue Regenix reported its first adjusted EBITDA profit for the year, +$0.9m, supported by revenue growth and cost management. We expect t
Companies: Tissue Regenix Group plc
Creo Medical has published a trading update for the 12 months to December 2023, during which the company focused on commercialising its core technology. Revenue for the period increased 13% YoY to £30.8m, while the underlying operating loss improved to £16.4m. Operationally, during the period, the number of confirmed users of Creo’s Speedboat range more than doubled over the year, the first procedures with MicroBlate Flex to ablate lung tumours were performed and Creo expects to receive regulato
Companies: Creo Medical Group Plc
Companies: NTQ KMK JNEO DCTA
LungLife AI is a medical diagnostics company focused on the development of AI-supported blood-based tests for the early detection of lung cancer. It has identified a significant medical need for non-invasive, sensitive and specific tests in early-stage lung cancer. The company’s core technology, the LungLB test, seeks to detect circulating tumour cells (CTCs) to identify malignant lung nodules. It aims to apply machine learning/AI (ML/AI) to derive algorithms to increase test accuracy. Following
Companies: LungLife AI, Inc.
This month's feature article is entitled 'Gold and a Chinese Credit Event'. A Western phenomenon? If you own, or are considering owning, gold or gold equities, it’s likely that you’re concerned about protecting your wealth, or the performance of your fund, in the expectation of some kind of financial instability. Maybe your confidence in policymakers is ebbing, or you’ve researched debt bubbles in history and concluded that physical gold and silver have been the safest places to be invested whe
Companies: NBPE ICGT ARBB CSN RECI CLIG HAT AVO STX VTA APAX
Share: